Healthcare / Medical DevicesStockholm
$55.00
-0.50 (-0.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-9.7M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
39.6x
↑ROE
-4.1%
↓Gross Margin
66.6%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+29.0%
FCF CAGR
—
FCF margin
-5.1%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $313.3M · net income $-16.7M · FCF $-16.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $313.3M | $313.3M | $253.0M | $210.1M | $145.9M |
| Net Income | $-16.7M | $-16.7M | $40.2M | $8.3M | $-10.3M |
| EBITDA | $29.9M | $29.9M | $58.9M | $31.2M | $16.2M |
| EPS | -0.72 | -0.72 | 2.11 | 0.44 | -0.54 |
| Gross Margin | 66.6% | 66.6% | 69.3% | 69.7% | 69.5% |
| Operating Margin | 1.4% | 1.4% | 13.2% | 6.0% | -0.9% |
| Net Margin | -5.3% | -5.3% | 15.9% | 4.0% | -7.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.09 | 0.11 | 0.15 |
| Current Ratio | 3.74 | 3.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.1M | $-16.1M | $15.4M | $-9.7M | $-33.0M |
| Returns | |||||
| ROE | -4.1% | -4.1% | 24.5% | 6.8% | -9.0% |
| Valuation | |||||
| P/E | — | — | 33.08 | 82.95 | — |
| EV/EBITDA | 39.57 | 39.57 | 22.18 | 21.93 | 49.93 |
| P/B | 3.19 | 3.19 | 8.12 | 5.68 | 7.27 |
| Growth & Yield | |||||
| Revenue Growth | 23.8% | 23.8% | 20.4% | 44.0% | — |
| EPS Growth | -134.1% | -134.1% | 379.5% | 181.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.5%
Start / end P/E
n/dx → n/dx
EPS bridge
2.11 → -0.72
Residual
-24.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.